Currently, there is no clinical study showing a correlation of CCL17 with the outcome of NSCLC patients but in other cancers, a high number of CCL17+ TANs within the tumor was correlated with a worse prognosis and tumor progression in hepatocellular carcinoma patients. This evidence concerns the gene CCL17 and cancer.